Qing, X. (2017). CRISPR/CAS9 AND PIGGYBAC MEDIATED LRRK2-G2019S IN VITRO PARKINSON’S DISEASE MODELING [Doctoral thesis, Unilu - University of Luxembourg]. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/31956 |
Spathis, A., Asvos, X., Ziavra, D., Karampelas, T., Topouzis, S., Cournia, Z., Qing, X., Alexakos, P., Smits, L., Dalla, C., Rideout, H., Schwamborn, J. C., Tamvakopoulos, C., Fokas, D., & Vassilatis, D. (2017). Nurr1:RXRα heterodimer activation as monotherapy for Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America. doi:10.1073/pnas.1616874114 Peer Reviewed verified by ORBi |
Arias, J., Jarazo, J., Qing, X., Walter, J., Gomez Giro, G., Nickels, S., Zaehres, H., Schoeler, H. R., & Schwamborn, J. C. (2017). FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling. Stem Cell Reports. doi:10.1016/j.stemcr.2017.08.026 Peer Reviewed verified by ORBi |